Welcome to our dedicated page for Alamar Biosciences SEC filings (Ticker: ALMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alamar Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alamar Biosciences's regulatory disclosures and financial reporting.
Alamar Biosciences director Rebecca Chambers reported an internal restructuring of stock options, not an open-market trade. One option covering 140,612 shares of Common Stock at an exercise price of $7.60 per share is now recorded as outstanding, while a corresponding option tied to 140,612 shares of Class B Common Stock was removed.
Each share of Class B Common Stock was reclassified into one share of Common Stock immediately before the company’s initial public offering, and the option reflects that change. Twenty-five percent of the option vests on January 15, 2027, with the remaining shares vesting in equal monthly installments over the following three years, and the option expires on January 14, 2036.
Alamar Biosciences director Frank Witney reported internal option restructurings related to the company’s share reclassification. On April 20, 2026, six Form 4 transactions with code J moved stock options between underlying Class B Common Stock and Common Stock at no transaction price.
The filing shows options for 124,069 shares at an exercise price of $7.60 expiring on January 14, 2036, 33,085 shares at $3.10 expiring on April 15, 2035, and 49,627 shares at $0.59 expiring on April 20, 2031. A footnote states each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering.
Alamar Biosciences President Timothy Ogden White reported equity awards and restructuring of his holdings in connection with the company’s initial public offering. On April 20, 2026, he received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing his direct Common Stock holdings to 491,803 shares.
The filing also shows multiple Class B Common Stock and related stock options being reclassified into equivalent Common Stock immediately prior to completion of the IPO, with no cash changing hands. Separately, on April 16, 2026, he was granted a stock option for 163,358 shares of Common Stock at an exercise price of $17.00 per share, vesting over time beginning in 2027.
Alamar Biosciences Chief Operating Officer Shiping Chen reported equity compensation grants and pre‑IPO share conversions, with no open‑market buying or selling. Chen received 37,220 shares of Common Stock as restricted stock units that vest monthly, bringing direct Common Stock holdings to 760,105 shares after the award.
The filing also shows automatic conversions of Class A Common Stock, Founders Preferred Stock, Series A‑1 Preferred Stock and Class B Common Stock into Common Stock immediately before Alamar’s IPO, plus administrative reclassifications of related stock options. Chen was granted a new stock option over 163,358 shares at $17.00 per share, alongside existing options with lower exercise prices.
Alamar Biosciences CEO Yuling Luo reported a series of equity restructurings and awards around the company’s initial public offering. Several classes of preferred and Class A shares automatically converted into Class B Common Stock and were then reclassified into Common Stock immediately before the IPO, with no cash changing hands.
The filing also shows a grant of 76,509 restricted stock units that vest monthly, and a new stock option for 341,191 shares of Common Stock at an exercise price of $17.00 per share, vesting over four years. Many option entries reflect technical reclassifications between Class B Common Stock and Common Stock rather than market trades.
Alamar Biosciences Chief Financial Officer Justin J. McAnear reported new equity awards and an option restructuring. He received 37,220 shares of Common Stock as restricted stock units that vest monthly from the grant date, conditioned on his continued service.
He was also granted stock options for 163,358 shares of Common Stock at an exercise price of $17.00 per share, with 25% vesting on April 16, 2027 and the remainder vesting in equal monthly installments thereafter, subject to continued service. In addition, 570,719 stock options with a $4.62 exercise price were reclassified so the underlying security changed from Class B Common Stock to Common Stock in connection with the company’s initial public offering, with no open-market buying or selling reported.
Alamar Biosciences director Nicholas Naclerio reported multiple equity-related transactions. An entity associated with him purchased 235,294 shares of Common Stock at $17.00 per share, increasing indirect ownership. He also received 5,686 restricted stock units that vest in three equal installments on April 20, 2027, April 20, 2028 and April 20, 2029, contingent on continued service.
In addition, he was granted a stock option for 25,599 shares at an exercise price of $17.00 per share, vesting from April 16, 2027 through April 16, 2029 and expiring on April 15, 2036. Several series of Preferred Stock and a convertible promissory note held by Illumina Innovation Fund entities automatically converted into Class B Common Stock, which was then reclassified into Common Stock in connection with the company’s IPO, with Naclerio disclaiming beneficial ownership except for his pecuniary interests.
Alamar Biosciences, Inc. completed its initial public offering of common stock on April 20, 2026. The company sold 12,937,500 shares, including 1,687,500 shares from the full exercise of the underwriters’ option, at $17.00 per share, generating approximately $219.9 million in gross proceeds before fees and expenses.
Immediately before the IPO closing, Alamar implemented an amended and restated certificate of incorporation and amended and restated bylaws, previously approved by its board and stockholders, to establish its post‑IPO corporate governance framework.
Alamar Biosciences, Inc. filed a Post-Effective Amendment No. 1 to its Form S-1 (Registration No. 333-294697) to replace Exhibit 5.1. The amendment is limited to Item 16(a) and Exhibit updates and states the registration statement shall become effective upon filing in accordance with Rule 462(d).
Alamar Biosciences, Inc. received an initial Form 3 from several Qiming-affiliated investment vehicles reporting indirect ownership of multiple series of preferred stock. These preferred shares are convertible into Class B Common Stock and will automatically convert into common stock upon the closing of the company’s initial public offering pursuant to their terms.
The filing shows holdings of Series A-3, Series A-4, Series B and Series C Preferred Stock, all with a stated conversion feature and no expiration date. Qiming Corporate GP VI, Ltd., Qiming GP VIII, LLC and Qiming GP VIII-HC, LLC may be deemed to have voting and dispositive power over certain positions but each disclaims beneficial ownership beyond its proportionate pecuniary interest.